There it is in the Annual Report that BIG PHARMA Are particularly interested in the "replication cycle" and there has been considerable interest in the outcomes of the HCV trials.
So with many patients suffering from both diseaes this is a must have drug.
A deal might not be far off. Whether its a sale or a partner. The one company might want both. At the level BIT have taken thi to, a significant upfront wold be part of any deal.
Just because the market has not responded yet, does not mean it wont.
Ann: Letter to Shareholders , page-3
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.0¢ |
Change
-0.001(4.76%) |
Mkt cap ! $18.04M | |||
| Open | High | Low | Value | Volume |
| 2.1¢ | 2.1¢ | 2.0¢ | $12.00K | 600.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 972631 | 1.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.1¢ | 199783 | 1 |
View Market Depth
| Last trade - 14.33pm 01/11/2024 (20 minute delay) ? |
| BIT (ASX) Chart |